Stockscreener 앱 받기
22.37
1.45%
-0.33
시간 외 거래:
22.37
전일 마감가:
$22.70
열려 있는:
$22.5
하루 거래량:
1.82M
Relative Volume:
0.88
시가총액:
$3.77B
수익:
$890.53M
순이익/손실:
$30.57M
주가수익비율:
124.28
EPS:
0.18
순현금흐름:
$80.53M
1주 성능:
-2.70%
1개월 성능:
+2.61%
6개월 성능:
+50.03%
1년 성능:
+51.05%
1일 변동 폭
$21.87
$22.78
1주일 범위
$21.87
$23.05
52주 변동 폭
$13.40
$26.65
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
명칭
Acadia Pharmaceuticals Inc
전화
858-558-2871
주소
12830 EL CAMINO REAL, SAN DIEGO
ACAD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
22.37 | 3.83B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-05-21 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2025-01-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-08-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-12 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-12 | 재확인 | Needham | Buy |
| 2024-01-30 | 개시 | Robert W. Baird | Outperform |
| 2024-01-24 | 업그레이드 | Needham | Hold → Buy |
| 2023-12-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-06 | 업그레이드 | Mizuho | Neutral → Buy |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-10-10 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-11-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-11-01 | 개시 | Loop Capital | Hold |
| 2022-08-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-08-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-06-21 | 다운그레이드 | Jefferies | Buy → Underperform |
| 2022-06-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-03-16 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-12-21 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-11-01 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-06-10 | 개시 | Berenberg | Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-04-06 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-04-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-05 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-03-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-03-09 | 재확인 | H.C. Wainwright | Buy |
| 2021-03-09 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-11-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 개시 | Morgan Stanley | Overweight |
| 2020-07-07 | 업그레이드 | Stifel | Hold → Buy |
| 2020-04-16 | 개시 | Jefferies | Buy |
| 2020-03-31 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2019-12-16 | 개시 | Guggenheim | Buy |
| 2019-10-24 | 개시 | Oppenheimer | Perform |
| 2019-10-01 | 개시 | RBC Capital Mkts | Outperform |
| 2019-09-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 재확인 | Needham | Buy |
| 2018-12-10 | 개시 | Canaccord Genuity | Hold |
| 2018-09-21 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 재확인 | Stifel | Hold |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-08-06 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 재개 | Goldman | Neutral |
모두보기
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
ACADIA Pharmaceuticals board member Daniel Soland resigns - StreetInsider
[8-K] ACADIA PHARMACEUTICALS INC Reports Material Event | ACAD SEC FilingForm 8-K - Stock Titan
How ACADIA Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Understanding ACADIA Pharmaceuticals Inc.’s price movementFed Meeting & Real-Time Buy Signal Alerts - newser.com
Is ACADIA Pharmaceuticals Inc. stock trading near support levelsWeekly Trade Summary & Low Risk Growth Stock Ideas - newser.com
Price momentum metrics for ACADIA Pharmaceuticals Inc. explainedWeekly Risk Report & High Conviction Trade Alerts - newser.com
Will ACADIA Pharmaceuticals Inc. stock split again soonJuly 2025 Volume & Daily Stock Trend Watchlist - newser.com
Why ACADIA Pharmaceuticals Inc. stock remains undervaluedMarket Trend Summary & High Conviction Buy Zone Alerts - newser.com
Is ACADIA Pharmaceuticals Inc. stock a top momentum playJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Reactions & AI Powered Market Entry Ideas - newser.com
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo! Finance UK
Why ACADIA Pharmaceuticals Inc. stock is rated strong buyRisk Management & Weekly Setup with ROI Potential - newser.com
ACADIA Pharmaceuticals Inc. (ACAD) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
EBITDA per share of ACADIA Pharmaceuticals Inc. – DUS:DR6 - TradingView
Is ACADIA Pharmaceuticals Inc. reversing from oversold territoryJuly 2025 Action & Weekly High Potential Alerts - newser.com
What drives ACADIA Pharmaceuticals Inc stock priceStock Buyback Announcements & Fast Growing Trading Plans - earlytimes.in
Ranking ACADIA Pharmaceuticals Inc. among high performing stocks via toolsQuarterly Trade Report & Daily Market Momentum Tracking - newser.com
ACADIA Pharmaceuticals Surges 53% as New Product Launches Fuel Fresh Valuation Debate - Sahm
ACADIA Pharmaceuticals Advances Phase 3 Study for Lewy Body Dementia Psychosis Treatment - MSN
Why ACADIA Pharmaceuticals Inc. stock appeals to dividend seekersMarket Activity Summary & Safe Entry Point Alerts - newser.com
How ACADIA Pharmaceuticals Inc. stock performs after earningsJuly 2025 Weekly Recap & Community Supported Trade Ideas - newser.com
Emerald Mutual Fund Advisers Trust Sells 175,778 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
How sentiment analysis helps forecast ACADIA Pharmaceuticals Inc.2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com
Is ACADIA Pharmaceuticals Inc. stock supported by strong fundamentalsTrend Reversal & Stepwise Swing Trade Plans - newser.com
Real time alert setup for ACADIA Pharmaceuticals Inc. performanceJuly 2025 Sector Moves & Consistent Profit Trade Alerts - newser.com
Acadia Pharma plots space to grow at Kilroy's big South San Francisco campus - The Business Journals
ACADIA Pharmaceuticals (ACAD): Exploring Valuation as Investor Interest Rises on Pipeline Momentum - Yahoo Finance
Emerald Advisers LLC Sells 223,547 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Advances Study on Carbetocin Nasal Spray for Prader-Willi Syndrome - MSN
ACADIA’s ACP-204 Study: A Promising Step for Alzheimer’s Disease Psychosis Treatment - MSN
12,050 Shares in ACADIA Pharmaceuticals Inc. $ACAD Bought by Yorktown Management & Research Co Inc - MarketBeat
ACADIA Pharmaceuticals (ACAD): Exploring Valuation After Strong Share Price Momentum and Pipeline Progress - Sahm
ACADIA Pharmaceuticals (ACAD) to Release Quarterly Earnings on Wednesday - MarketBeat
Acadia Pharmaceuticals Inc (ACAD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):